270 related articles for article (PubMed ID: 32173916)
1. Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis.
Yamamoto T; Fukuda K; Morita A; Kimura T; Morishima H; Goto R; Zheng R; Terui T
J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2318-2329. PubMed ID: 32173916
[TBL] [Abstract][Full Text] [Related]
2. Guselkumab improves joint pain in patients with pustulotic arthro-osteitis: A retrospective pilot study.
Ikumi N; Fujita H; Terui T
J Dermatol; 2021 Feb; 48(2):199-202. PubMed ID: 33051886
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
[TBL] [Abstract][Full Text] [Related]
4. Utility of nailfold capillary assessment for predicting pustulotic arthro-osteitis in palmoplantar pustulosis based on a prospective cohort study.
Fukasawa T; Yamashita T; Enomoto A; Toyama S; Yoshizaki-Ogawa A; Tateishi S; Kanda H; Miyagawa K; Sato S; Yoshizaki A
J Am Acad Dermatol; 2023 Nov; 89(5):984-991. PubMed ID: 37517674
[TBL] [Abstract][Full Text] [Related]
5. Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective.
Yamamoto T
Clin Pharmacol; 2021; 13():135-143. PubMed ID: 34188558
[TBL] [Abstract][Full Text] [Related]
6. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.
Okubo Y; Morishima H; Zheng R; Terui T
J Dermatol; 2021 Dec; 48(12):1838-1853. PubMed ID: 34453358
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes.
Ueno M; Miyagawa I; Miyazaki Y; Hanami K; Fukuyo S; Kubo S; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2022 Oct; 24(1):240. PubMed ID: 36303202
[TBL] [Abstract][Full Text] [Related]
8. Guselkumab for the treatment of palmoplantar pustulosis.
Murakami M
Expert Opin Biol Ther; 2020 Aug; 20(8):841-852. PubMed ID: 32321322
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of pustulotic arthro-osteitis in Korea.
Kim M; Kim M; Kim JW; Kim BR; Youn SW
J Dermatol; 2022 Aug; 49(8):762-768. PubMed ID: 35510638
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
Curtis JR; McInnes IB; Rahman P; Gladman DD; Yang F; Peterson S; Agarwal P; Kollmeier AP; Hsia EC; Han C; Shiff NJ; Shawi M; Tillett W; Mease PJ
Adv Ther; 2022 Oct; 39(10):4632-4644. PubMed ID: 35947348
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Zheng R; Morishima H; Goto R; Kimura T
JAMA Dermatol; 2019 Oct; 155(10):1153-1161. PubMed ID: 31268476
[TBL] [Abstract][Full Text] [Related]
13. Dietary habits in Japanese patients with palmoplantar pustulosis.
Serizawa N; Okazaki S; Otsuka Y; Koto M; Okabe K; Ito M; Morita T; Hoashi T; Saeki H; Abe N; Mori M; Okubo Y; Yano Y; Mitsui H; Kanda N
J Dermatol; 2021 Mar; 48(3):366-375. PubMed ID: 33404125
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics of Japanese Patients with Palmoplantar Pustulosis.
Yamamoto T
Clin Drug Investig; 2019 Mar; 39(3):241-252. PubMed ID: 30632109
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
17. Nail lesions in palmoplantar pustulosis and pustulotic arthro-osteitis impairs patients' quality of life: Suggesting new assessment tool of PPP nail lesions.
Masuda-Kuroki K; Kawakami H; Abe N; Mori M; Tobita R; Fukushi R; Hiruma J; Takeda Y; Okubo Y
J Dermatol Sci; 2022 Apr; 106(1):29-36. PubMed ID: 35307234
[TBL] [Abstract][Full Text] [Related]
18. Palmoplantar pustulosis and pustulotic arthro-osteitis associated with multiple venous occlusion: A case report and literature review.
Inoue E; Hiroumi S; Sato S; Hayashi M; Konaka H; Tsuji S; Higashiyama M
J Dermatol; 2023 Aug; 50(8):1076-1080. PubMed ID: 37017424
[TBL] [Abstract][Full Text] [Related]
19. Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients.
Hayashi S; Shimaoka Y; Hamasaki Y; Hatamochi A
Int J Dermatol; 2017 Aug; 56(8):889-893. PubMed ID: 28369847
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
